First Time Loading...

Calithera Biosciences Inc
NASDAQ:CALA

Watchlist Manager
Calithera Biosciences Inc Logo
Calithera Biosciences Inc
NASDAQ:CALA
Watchlist
Price: 0.02 USD Market Closed
Updated: Mar 28, 2024

Intrinsic Value

CALA doesn't have a meaningful market cap.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor a... [ Read More ]

There is not enough data to reliably calculate the intrinsic value of CALA.

Key Points:
CALA Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Calithera Biosciences Inc's business.

What risks and challenges
does Calithera Biosciences Inc face in the near future?

Summarize the latest earnings report
of Calithera Biosciences Inc.

Provide P/E
for Calithera Biosciences Inc and its competitors.

Financials

Balance Sheet Decomposition
Calithera Biosciences Inc

Current Assets 26.6m
Cash & Short-Term Investments 25.5m
Other Current Assets 1.1m
Non-Current Assets 2.1m
PP&E 1.8m
Other Non-Current Assets 300k
Current Liabilities 7.4m
Accounts Payable 700k
Accrued Liabilities 6.7m
Non-Current Liabilities 900k
Other Non-Current Liabilities 900k
Efficiency

Earnings Waterfall
Calithera Biosciences Inc

Revenue
0 USD
Operating Expenses
-42.1m USD
Operating Income
-42.1m USD
Other Expenses
20.8m USD
Net Income
-21.3m USD

Free Cash Flow Analysis
Calithera Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CALA Profitability Score
Profitability Due Diligence

Calithera Biosciences Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Calithera Biosciences Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

CALA Solvency Score
Solvency Due Diligence

Calithera Biosciences Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
58/100
Solvency
Score

Calithera Biosciences Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CALA Price Targets Summary
Calithera Biosciences Inc

There are no price targets for CALA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CALA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CALA Price
Calithera Biosciences Inc

1M 1M
+0%
6M 6M
-60%
1Y 1Y
-50%
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
0.02
52w Low
0.02
52w High
0.37
Price Metrics
Average Annual Return -55.04%
Standard Deviation of Annual Returns 27.01%
Max Drawdown -100%
Shares Statistics
Market Capitalization 98k USD
Shares Outstanding 4 872 500
Percentage of Shares Shorted 8.92%

CALA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Calithera Biosciences Inc Logo
Calithera Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

98k USD

Dividend Yield

0%

Description

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The firm is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. The company has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. The company has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The firm is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).

Contact

CALIFORNIA
South San Francisco
343 Oyster Point Blvd # 200
+16508701000.0
http://www.calithera.com/

IPO

2014-10-02

Employees

63

Officers

Founder, CEO, President & Director
Dr. Susan M. Molineaux Ph.D.
CFO & Secretary
Ms. Stephanie Wong
Senior Vice President of Development
Dr. Christopher J. Molineaux Ph.D.
Senior Vice President of Research
Mr. Frank Parlati Ph.D.

See Also

Discover More